The use of nasal decongestants in ENT practice
- Autores: Morozova E.S1, Svistushkin V.М.1
-
Afiliações:
- Sechenov First Moscow State Medical University (Sechenov University)
- Edição: Volume 27, Nº 5 (2020)
- Páginas: 102-105
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312650
- DOI: https://doi.org/10.18565/pharmateca.2020.5.102-104
- ID: 312650
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Problems with nasal breathing are one of the main complaints that are addressed to the otorhinolaryngologist in everyday practice. Elimination of edema of the mucous membrane of the nasal cavity and natural anastomoses of the paranasal sinuses is the basis of therapy to restore the normal physiology of the upper respiratory tract. The most popular drugs for elimination of the nasal obstruction are topical decongestants, which have a strong and rapid effect. One of these drugs is Otrivin® complex.
Palavras-chave
Texto integral
Sobre autores
E. Morozova
Sechenov First Moscow State Medical University (Sechenov University)Moscow, Russia
Valery Svistushkin
Sechenov First Moscow State Medical University (Sechenov University)
Email: swm3@yandex.ru
Dr. Sei. (Med.), Professor, Director of the Clinic, Head of the Department of Ear, Nose and Throat Diseases 6, build. 1, Bolshaya Pirogovskaya str., Moscow 119435, Russian Federation
Bibliografia
- Passali D., Buccellam G., Vetuschi A., Bellussi L. Nasal vascularization: experiences using the microcorrosion technique in human foetuses. Rhinology. 1992;30(2):81-8.
- Мирошниченко Н.А., Овчинников А.Ю. Топические деконгестанты. Мифы и реальность. Медицинский совет. 2018;(12):40-3.
- Togias A. Mechanism of nose-lung interaction. Allergy. 1999;54(Suppl. 57):94-100.
- Лопатин А.С. Ринит: руководство для врачей. М., 2010. 424 с.
- Пискунов Г.З., Пискунов С.З. Клиническая ринология. Руководство для врачей. М., 2006. 560 с.
- Грищенко Е.Б. Назальные деконгестанты в отрино-ларингологии. Медицинский совет. 2012;2:28-31.
- Сампиева К.Т., Ивашев М.Н. Классификация декон-гестантов. Международный журнал экспериментального образования. 2016;6-1:84-4.
- Malm L., Anggard L. Vasoconstrictors. in: N. Mygind, R.M. Naclerio, eds. Allergic and non-allergic rhinitis. Clinical aspects. Copenhagen: Munksgaard, 1993. P. 95-100.
- Caenen M., et al. Comparison of decongestive capacity of xylometazoline and pseudoephedrine with rhinomanometry and MRi. Rhinology 2005;43(3):205-9.
- Graf P Rhinitis medicamentosa: a review of causes and treatment. Treat Respir Med. 2005;4:21-9. doi: 10.2165/00151829-200504010-00003
- Lockey R.F Rhinitis medicamentosa and the stuffy nose. J Allergy Clin immunol. 2006;118:1017-18. doi: 10.1016/j.jaci.2006.06.018.
- Petruson B., Hansson H. Function and structure of nasal mucosa after 6 weeks use of nose-drops. Acta Otolaryngol. 1982;94(5-6):563-69. doi: 10.3109/00016488209128948.
- Beck-Speier i., et al. Oxymetazoline inhibits proinflammatory reactions: effect on arachidonic acid-derived metabolites. J Pharmacol Exp Ther. 2006;316(2):6843-51. Doi: 10.1124/ jpet.105.093278.
- Лопатин А.С. Назальные деконгестанты: старые препараты и новые формы. Оториноларингология. 2011 ;6(65):17-23.
- Крюков А.И., Кунельская Н.Л., Изотова Е.Н. и др. Подходы к терапии острого ринита. Медицинский совет. 2016;9:45-7.
- Hayden E.G., Diamond L, Wood P.B, et al. Effectiveness and safety of intranasal ipratropium bromide in common colds. A randomized, doubleblind, placebo-controlled trial. Ann Intern Med. 1996;125(2):89-97. doi: 10.7326/0003-4819-125-2-199607150-00002.
- Eccles R., Pedersen A., Regberg D, et al. Efficacy and safety of topical combinations of ipratopium and xylometazoline for the treatment of symptoms of runny nose and nasal congestion associated withacute upper respiratory tract infection. Am Rhinol. 2007;21:40-5. doi: 10.2500/ar. 2007.21.2902.
- Инструкция по применению препарата Отривин® комплекс. Поступила/ Received: 07.04.2020 Принята в печать /Accepted: 30.04.2020
Arquivos suplementares
